Overcoming breast cancer resistance through targeted protein degradation and next generation chimeras
Pharmacological Research · 2026-07 · 229 · 108239
DOI: 10.1016/j.phrs.2026.108239 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacological Research, 2026-07. Verfasst von Xinyao Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Breast Neoplasms, Drug Resistance, Neoplasm, Proteolysis Targeting Chimera. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Zhejiang Chinese Medical University, Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
Proteolysis-Targeting Chimeras (PROTACs) represent a paradigm shift from occupancy-driven inhibition to event-driven protein elimination in cancer therapy. By harnessing the ubiquitin-proteasome system, PROTACs catalytically degrade disease-driving proteins. In breast cancer, the most commonly diagnosed cancer in women globally, PROTAC technology has advanced rapidly from preclinical concept to clinical validation. This review systematically evaluates PROTAC development across multiple therapeutic targets in breast cancer, including estrogen receptor α (ERα), human epidermal growth factor receptor 2 (HER2), bromodomain-containing protein 4 (BRD4), poly(ADP-ribose) polymerase 1 (PARP1), cyclin-dependent kinases 4/6 (CDK4/6), and enhancer of zeste homolog 2 (EZH2). We discuss structure-guided design principles, ternary complex formation mechanisms, and pharmacokinetic/pharmacodynamic profiles. Notably, the ERα degrader vepdegestrant (ARV-471) achieved positive Phase III results in the VERITAC-2 trial, demonstrating significant progression-free survival benefit in ESR1-mutant ER+ /HER2- breast cancer, marking a milestone for PROTAC clinical translation. Preclinical studies of HER2, BRD4, and other PROTACs show promising efficacy with DC50 values in the nanomolar range and superior tumor growth inhibition compared to conventional inhibitors. However, challenges remain in optimizing oral bioavailability, minimizing off-target effects, and overcoming resistance mechanisms including target protein loss and E3 ligase pathway alterations. Emerging technologies such as lysosome-targeting chimeras (LYTAC) and next-generation E3 ligases expand the druggable target space. With over 30 PROTACs currently in clinical trials across oncology, this review provides a comprehensive analysis of PROTAC applications in breast cancer and outlines future directions for precision medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China.
- School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China. Electronic address: taoff@zcmu.edu.cn.
- School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China. Electronic address: xuye@zcmu.edu.cn.
Förderung
- Zhejiang Chinese Medical University
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Wang, X., Song, J., Zhao, Y., Li, W., Li, J., Xu, X., Liu, W., Tao, F., & Xu, Y. (2026). Overcoming breast cancer resistance through targeted protein degradation and next generation chimeras. Pharmacological Research, 229, 108239. https://doi.org/10.1016/j.phrs.2026.108239
Vancouver
Wang X, Song J, Zhao Y, Li W, Li J, Xu X, et al. Overcoming breast cancer resistance through targeted protein degradation and next generation chimeras. Pharmacological Research. 2026;229:108239. doi:10.1016/j.phrs.2026.108239
BibTeX
@article{Wang2026,
author = {Wang, Xinyao and Song, Jiawen and Zhao, Yuan and Li, Wei and Li, Junfeng and Xu, Xuefei and Liu, Wenhong and Tao, Fangfang and Xu, Ye},
title = {Overcoming breast cancer resistance through targeted protein degradation and next generation chimeras},
journal = {Pharmacological Research},
year = {2026},
volume = {229},
pages = {108239},
doi = {10.1016/j.phrs.2026.108239}
}
EUVIMED